Cybin (CYBN) Stock Price, News & Analysis

Company Overview

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $7.44 to $7.91
• 50-Day Range: $7.01 to $9.00
• 52-Week Range: $4.81 to $13.88
• Volume: 249,122 shs
• Average Volume: 315,249 shs
• Market Capitalization: $179.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $85.00
• Consensus Rating: Buy

Cybin Stock Analysis - MarketRank™

Cybin scored higher than 55% of companies evaluated by MarketBeat, and ranked 534th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Cybin has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cybin has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cybin are expected to grow in the coming year, from ($4.76) to ($4.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cybin is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cybin is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cybin has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CYBN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cybin does not currently pay a dividend.

Dividend Growth

Cybin does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CYBN.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.34

News Sentiment

Cybin has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cybin this week, compared to 1 article on an average week.

Search Interest

19 people have searched for CYBN on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.

MarketBeat Follows

22 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 340% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cybin insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.94% of the stock of Cybin is held by institutions.

CYBN Stock Analysis - Frequently Asked Questions

How have CYBN shares performed this year?

Cybin's stock was trading at $8.82 at the start of the year. Since then, CYBN stock has decreased by 15.3% and is now trading at $7.47.

How were Cybin's earnings last quarter?

Cybin Inc. (NYSE:CYBN) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04).

How do I buy shares of Cybin?

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cybin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), FuelCell Energy (FCEL), Meta Platforms (META), Aurora Cannabis (ACB), AlTi Global (ALTI), UiPath (PATH) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 7/29/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CYBN
• Previous Symbol: NYSE:CYBN
• CIK: 1833141
• Web: www.cybin.com
• Phone: 908-764-8385
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cybin: $85.00
• High Price Target: $150.00
• Low Price Target: $35.00
• Potential Upside/Downside: +1,027.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.58%
• Return on Assets: -36.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.24
• Quick Ratio: 24.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.83 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 23,590,000
• Free Float: 17,962,000
• Market Cap: $177.89 million
• Optionable: Not Optionable
• Beta: 0.69